头孢西丁钠治疗儿童社区获得性肺炎的疗效及安全性分析

Analysis on the therapeutic efficacy and safety of cefoxitin sodium in the treatment of children with community-acquired pneumonia

目的分析头孢西丁钠治疗儿童社区获得性肺炎(CAP)的临床疗效及安全性。方法选取泰安市妇幼保健院2018年5月至2020年5月住院治疗的72例CAP患儿,以单盲随机抽样法分两组,每组各36例。参照组采纳头孢呋辛治疗,试验组采纳头孢西丁钠治疗,两组均在用药7 d后评价治疗效果,比较两组临床疗效、临床症状消失时间、血清炎症因子、不良反应发生率、复发率。结果试验组临床总有效率(94.44%)高于参照组(72.22%),试验组肺部啰音、咳痰、咳嗽、发热消失时间均短于参照组,试验组治疗7 d后血清肿瘤坏死因子(TNF-α)、白细胞介素-6(IL-6)、超敏C反应蛋白(hs-CRP)、降钙素原(PCT)因子均低于参照组,试验组复发率(2.78%)低于参照组(19.44%),差异均有统计学意义(P<0.05)。试验组不良反应发生率(5.56%)与参照组(8.33%)比较,差异无统计学意义(P>0.05)。结论头孢西丁钠可有效缓解CAP患儿咳嗽、咳痰等症状,减轻炎症反应,降低复发率,不会增加不良反应,值得借鉴。

Objective To analyze the clinical efficacy and safety of cefoxitin sodium in the treatment of children with community-acquired pneumonia(CAP).Methods A total of 72 children with CAP admitted to Tai’an Maternal and Child Health Hospital from May 2018 to May 2020 were selected and divided into the control group(n=36)and the experimental group(n=36)according to single blind random sampling method.The control group was treated with cefuroxime,while the experimental group was treated with cefoxitin sodium.The therapeutic efficacy was evaluated in both groups after 7 days of treatment.The clinical efficacy,disappearance time of clinical symptoms,serum inflammatory factors,incidence of adverse reactions(ADRs)and relapse rate of the two groups were compared.Results The total clinical efficacy rate of the experimental group was 94.44%,higher than 72.22%of the control group.The disappearance time of lung rales,sputum,cough and fever in the experimental group was all shorter than that in the control group.The levels of serum TNF-a,IL-6,hs-CRP and PCT factors in the experimental group were all lower than those in the control group after 7 days of treatment,and the relapse rate in the experimental group was 2.78%,lower than 19.44%in the control group,with statistically significant differences(P<0.05).The incidence of ADRs in the experimental group was 5.56%,compared with 8.33%in the control group,there were on statistically significant difference(P>0.05).Conclusion Cefoxitin sodium can effectively relieve cough,sputum and other symptoms in children with CAP,alleviate inflammatory reactions and reduce relapse rate,with fewer ADRs,which is worthy of reference.